EUCTR2011-002714-37-IT进行中（未招募）不适用
A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, ACTIVE-CONTROLLED,PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUGRO5024048 IN COMBINATION WITH BOCEPREVIR AND PEGASYS/COPEGUS COMPARED WITH BOCEPREVIR AND PEGASYS/COPEGUS IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 VIRUSINFECTION WHO WERE PRIOR NULL RESPONDERS TO TREATMENT WITHPEGYLATED INTERFERON/RIBAVIRIN
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ROCHE
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male or female aged 18 years and older - Serologic evidence of CHC infection by an anti-HCV antibody (Ab) test (current or historical) - Evidence of CHC infection > 6 months duration - Serum HCV RNA quantifiable at = 50,000 IU/mL as demonstrated by the Roche COBAS TaqMan HCV Test - Evidence of HCV genotype 1a or 1b infection by molecular assay - The following information related to the patient's response to the previous course of PEG-IFN/RBV therapy must be available in the medical records of the patient: (1) approved doses of prior PEGIFN/ RBV treatment and the start/end date of previous treatment with PEG-IFN/RBV, (2) documentation of previous dose modifications or interruptions (or lack thereof) to ensure documentation of previous compliance with therapy, (3) HCV RNA prior to the start of previous treatment and at 12 weeks after the start of treatment (window of Week 11 to Week 16) showing a null response, defined as a < 2 log10 IU/mL decrease in viral titer after at least 12 weeks of treatment with PEGIFN/ RBV, (4) HCV assay used, and (5) limit of detection of the assay used. - Chronic liver disease consistent with CHC infection as seen via biopsy, using the scoring methods in Appendix B. Patients not yet designated as having cirrhosis or incomplete/transition to cirrhosis must have had a liver biopsy consistent with CHC within 24 calendar months of the first dose. For patients with cirrhosis or incomplete/transition to cirrhosis, there is no time frame for the biopsy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 92
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 8
排除标准
- •- Positive test at screening for anti–hepatitis A virus (HAV) IgM Ab, hepatitis B surface antigen (HBsAg), or anti-HIV Ab - History of having received RO5024048/boceprevir or any crossresistant DAA agent at any previous time or use of any other systemic antiviral therapy with established or perceived activity against HCV = 3 months prior to the first dose of study drug - History of having received any investigational drug = 3 months prior to the first dose of study drug or the expectation that such drugs will be used during the study. - History or other evidence of a medical condition associated with chronic liver disease other than HCV (e.g., hemochromatosis, autoimmune hepatitis, Wilson's disease, alpha-1 antitrypsin deficiency, alcoholic liver disease, and/or toxin exposure) - Females who are pregnant or breastfeeding - Males with female partners who are pregnant - Absolute neutrophil count (ANC) < 1.5 × 103 cells/µL (< 1.5 × 109 cells/L) - Platelet count < 90 × 103 cells/µL (< 90 × 109 cells/L) - Hemoglobin concentration < 12 g/dL (120 g/L) in females or < 13 g/dL (130 g/L) in males or a baseline increased risk for anemia (e.g., thalassemia, sickle cell anemia, spherocytosis, history of gastrointestinal bleeding) or in those for whom anemia would be medically problematic - The use of colony-stimulating factors such as granulocyte colonystimulating factor (G-CSF), erythropoietin, blood transfusion, or other therapeutic agents to elevate hematology parameters to facilitate patient entry into the study within the last 6 months - Any patient with a history of severe psychiatric disease, including psychosis and/or depression, characterized by a suicide attempt, hospitalization for psychiatric disease, or a period of disability as a result of psychiatric disease who does not agree to have a psychiatric evaluation at screening and who does not agree to have continued monitoring by a mental health specialist at least every 4 weeks during the study - History of immunologically mediated disease (e.g., vasculitis, cryoglobulinemia, inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis requiring more than intermittent non-steroidal anti-inflammatory medications for management). - History or other evidence of decompensated liver disease. Coagulopathy, hyperbilirubinemia, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices are conditions consistent with decompensated liver disease. - Serum creatinine > 1.5 times the ULN - History of pre-existing renal disease. Patients with a history of nephrolithiasis will be allowed. - Estimated creatinine clearance (CRCL) of = 70 mL/min (= 1.17 mL/sec), calculated by the Cockcroft-Gault formula (see Appendix C) - Type 1 or 2 diabetes with glycosylated hemoglobin (HbA1c) of = 8.5% at the screening visit - History or other evidence of chronic pulmonary disease associated with functional limitation
研究者
相似试验
进行中（未招募）
不适用
A Study of RO5024048 in Combination With Boceprevir, Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 who were prior null responders to Pegylated Interferon/Ribavirin TreatmentChronic Hepatitis C (CHC), Genotype 1MedDRA version: 14.0Level: LLTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-002714-37-ESF. Hoffmann-La Roche Ltd100
进行中（未招募）
不适用
A Study of RO5024048 in Combination With Telaprevir, Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 who were prior null responders to Pegylated Interferon/Ribavirin TreatmentChronic Hepatitis C (CHC), Genotype 1MedDRA version: 14.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-002715-28-DEF. Hoffmann-La Roche Ltd140
进行中（未招募）
1 期
A Study of RO5024048 in Combination With Telaprevir, Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 who were prior null responders to Pegylated Interferon/Ribavirin TreatmentChronic Hepatitis C (CHC), Genotype 1MedDRA version: 14.1 Level: PT Classification code 10008912 Term: Chronic hepatitis C System Organ Class: 10021881 - Infections and infestationsEUCTR2011-002715-28-GBF. Hoffmann-La Roche Ltd80
进行中（未招募）
不适用
A Study of RO5024048 in Combination With Boceprevir, Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 who were prior null responders to Pegylated Interferon/Ribavirin TreatmentChronic Hepatitis C (CHC), Genotype 1MedDRA version: 14.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-002714-37-DEF. Hoffmann-La Roche Ltd100
进行中（未招募）
1 期
A Study of RO7247669 plus Platinum-Based Chemotherapy vs. Pembrolizumab plus Platinum-Based Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung CancerPreviously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2022-001440-18-FRF. Hoffmann La-Roche Ltd180